Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
<i>Background</i>: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine therapy is not uncommon. Over the past decades,...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2021-05-01
|
| Ráidu: | Current Oncology |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/1718-7729/28/3/168 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|